Derudas, Daniele

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?

Saltarella, I., Frassanito, M. A., Lamanuzzi, A., Brevi, A., Leone, P., Desantis, V., Di Marzo, L., Bellone, M., Derudas, D., Ribatti, D., et al. (2019) · Neoplasia

Multiple Myeloma Research and TreatmentsAngiogenesis and VEGF in Cancer

Cited by 32

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., et al. (2022) · International Journal of Molecular Sciences

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 17

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 17